lipid storage diseases
DESCRIPTION
Important lipid storage diseasesTRANSCRIPT
![Page 1: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/1.jpg)
Biochemistry For Medicshttp://www.namrata.co/
Published in Students corner
By- Shivanee Dunneram
Lipid Storage Diseases
![Page 2: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/2.jpg)
Lipid storage diseases
Presented by; Shivanee DunneramRoll no:18
![Page 3: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/3.jpg)
Introduction
Tay Sach Disease
Gaucher Disease
Niemann Pick Disease
Other lipid storage Diseases
Table of contents
![Page 4: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/4.jpg)
any of a group of relatively rare hereditary disorders of fat metabolism, characterized by the accumulation of distinctive types of lipids;
Gangliosides
cerebrosides, or
sphingomyelins, in various body structures.
Each type of lipid accumulates as a result of a defect in one of the several organic catalysts or enzymes that normally metabolize it inside the cell.
Introduction: lipid storage diseases or sphingolipidosis
![Page 5: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/5.jpg)
Tay Sach Disease: Biomedical defect• This is an inborn error of metabolism due to failure of degradation of gangliosides. • The enzyme hexosaminidase A is deficient.composed of an α and β subunitsMutation in α subunit,15q23
HEXOSAMINIDASE A
![Page 6: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/6.jpg)
Tay Sach disease: Inheritance
It is inherited as an autosomal recessive traits, with a predilection in the Ashkenazi Jewish population, where the carrier frequency is about 1/25.
![Page 7: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/7.jpg)
Tay Sach Disease: Clinical Symptoms and classification
Tay-Sachs disease is classified in variant forms, based on the time of onset of neurological symptoms. Infantile TSD
Birth: normal but develop Loss of motor skills Increased startle reaction Macullar pallor and retinal cherry red spot 5-6 months Decreased eye contact Hyperacusis Progressive development of idiocy and blindness are diagnostic of this disease and they are due to wide
spread injury to ganglion cells, in brain and retina.
![Page 8: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/8.jpg)
Tay Sach Disease: Clinical symptoms and Classication
Juvenile TSD extremely rare presents itself in children between 2 - 10
years develop cognitive, motor, speech difficulties (dysarthria), swallowing difficulties (dysphagia), unsteadiness of gait (ataxia), and spasticity. Patients with Juvenile TSD usually die between 5–15 years.
![Page 9: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/9.jpg)
Tay Sach Disease: Clinical symptoms and Classication
Adult/Late Onset TSD. rare form of the disorder occurs in patients in their 20s and
early 30s. It is characterized by unsteadiness of gait and progressive neurological deterioration. Symptoms of LOTS, include speech and swallowing difficulties, unsteadiness of gait, spasticity, cognitive decline, and psychiatric illness
![Page 10: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/10.jpg)
![Page 11: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/11.jpg)
Diagnosis of Tay-Sach diseaseis usually suspected in an infant with neurologic features and a cherry-red spot.
Enzymatic Assays-Definitive diagnosis is by determination of the level of ß-hexosaminidase A in isolated blood leukocytes.
Fine needle Aspiration Cytology of brain tissue – can show the degree of neuronal degeneration. FNAC has a great potential for diagnosis and follow-up of Tay-Sachs disease
Prenatal screening-Future at-risk pregnancies for both disorders can be monitored by prenatal diagnosis by amniocentesis or chorionic villus sampling.
Carrier screening- Identification of carriers within families is also possible by ß-hexosaminidase A and B determination.
![Page 12: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/12.jpg)
Treatment of Tay-Sach disease
No cure for this disease.
Symptomatic treatment is given.
Enzyme replacement therapy and Gene
therapy are under trial.
![Page 13: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/13.jpg)
Gaucher disease
This disease is a multisystem lipidosis characterized by hematological
changes, organomegaly and skeletal involvement, manifested in the form of
bone pains and multiple fractures.
It is the most common genetic disorder among
Ashkenazi Jews.
It is the commonest Lysosomal storage disease.
![Page 14: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/14.jpg)
Gaucher disease :Biochemical defect
• results from deficient activity of Lysosomal Hydrolase, β- Glucocerebrosidase.
• enzyme defect results in accumulation of undegraded glycolipid in the form of Glucosyl ceramide in the cells of reticuloendothelial system.
β- Glucocerebrosidase
![Page 15: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/15.jpg)
GAUCHER DISEASE: CLINICAL FEATURES
There are three clinical subtypes• 1)Type-1- (from early childhood-
adulthood)• easy bruising due to thrombocytopenia,
chronic fatigue due to anemia, hepatomegaly
• Progressive enlargement of spleen• Clinical bone involvement in the form of
bone pains, or pathological fractures.
![Page 16: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/16.jpg)
GAUCHER DISEASE: CLINICAL FEATURES
Type 2- • less common,• characterized by neurodegeneration,
extreme visceral involvement • death within 2 years of life. Type 3- • is intermediate in presentation to type 1 and
2.• Neurological involvement is there but
occurs later in life with decreased severity as compared to Type 2.
![Page 17: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/17.jpg)
Gaucher disease: Laboratory Diagnosis
• Enzyme activity testing: A finding of less than 15% of mean normal activity is diagnostic.• Genotype testing: Molecular diagnosis can be helpful, Especially in Ashkenazi patients.• Complete blood count: • to assess the degree of cytopenia.• Liver function enzyme testing: the presence of jaundice or impaired hepatocellular synthetic function
![Page 18: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/18.jpg)
Imaging studies Hip MRI may
be useful in revealing early avascular necrosis.
Ultrasonography
Skeletal radiography
Liver biopsy
![Page 19: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/19.jpg)
TreatmentEnzyme replacement therapy(ERT)
by recombinant β- Glucocerebrosidase
is currently done.
Surgical Care:
Partial and total Splenectomy was once advocated in the treatment of patients with Gaucher disease.
Bone marrow transplant is also helpful.
Gene replacement is the permanent cure.
![Page 20: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/20.jpg)
Niemann Pick disease: clinical significanceOccurs due to impaired degradation of shingomyelins.
There is deficiency of sphingomyelinase enzyme.
Due to non degradation, there is accumulation of shingomyelin in liver, spleen, bone marrow, and brain
![Page 21: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/21.jpg)
Niemann Pick disease: Inheritance
• Is a congenital disease• Autosomal recessive in nature• There are 2 types: A and B• Type A: more common present in 1/40000
population• Type B: present in 1/80000 population• More common in Jewish population
![Page 22: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/22.jpg)
Niemann Pick disease :Clinical manifestation
TypeA Niemann Pick disease: there is progressive mental retardation,
hepatosplenomegaly because of progressive accumulation of sphingomyelin• Children die within 2 years of lifeType B: there is no involvement of
brain but sphingomyelin is present in excessive amount in liver, spleen, and bone marrow.• Death occurs within 20 years of
life• Treatment: only symptomatic • treatment is given.
![Page 23: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/23.jpg)
Disease Enzyme Deficiency
Lipid Accumulating Clinical Symptoms
Tay Sach’s Disease Hexosaminidase A
GM2 Ganglioside Mental retardation, blindness, muscular weakness
Fabry's disease α-Galactosidase Globotriaosylceramide
Skin rash, kidney failure (full symptoms only in males; X-linked recessive).
Metachromatic leukodystrophy Arylsulfatase A Sulfogalactosylceramide
Mental retardation and Psychologic disturbances in adults; demyelination.
Krabbe's disease β-Galactosidase Galactosylceramide Mental retardation; myelin almost absent.
Gaucher's disease β -Glycosidase Glucosyl ceramide Enlarged liver and spleen, erosion of long bones, mental retardation in infants.
Niemann-Pick disease Sphingomyelinase
Sphigomyelin Enlarged liver and spleen, mental retardation; fatal in early life.
Farber's disease Ceramidase Ceramide Hoarseness, dermatitis, skeletal deformation, mental retardation; fatal in early life
![Page 24: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/24.jpg)
![Page 25: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/25.jpg)
References
Class notes
Internet
![Page 26: Lipid storage diseases](https://reader035.vdocuments.us/reader035/viewer/2022062300/554975acb4c905525e8b54a6/html5/thumbnails/26.jpg)